These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 36156061)

  • 1. Prescription Patterns of Cardiovascular- and Kidney-Protective Therapies Among Patients With Type 2 Diabetes and Chronic Kidney Disease.
    Lamprea-Montealegre JA; Madden E; Tummalapalli SL; Chu CD; Peralta CA; Du Y; Singh R; Kong SX; Tuot DS; Shlipak MG; Estrella MM
    Diabetes Care; 2022 Dec; 45(12):2900-2906. PubMed ID: 36156061
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association of Race and Ethnicity With Prescription of SGLT2 Inhibitors and GLP1 Receptor Agonists Among Patients With Type 2 Diabetes in the Veterans Health Administration System.
    Lamprea-Montealegre JA; Madden E; Tummalapalli SL; Peralta C; Neilands TB; Garcia PK; Muiru A; Karliner L; Shlipak MG; Estrella MM
    JAMA; 2022 Sep; 328(9):861-871. PubMed ID: 36066519
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of the Effects of Glucagon-Like Peptide Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors for Prevention of Major Adverse Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus.
    Zelniker TA; Wiviott SD; Raz I; Im K; Goodrich EL; Furtado RHM; Bonaca MP; Mosenzon O; Kato ET; Cahn A; Bhatt DL; Leiter LA; McGuire DK; Wilding JPH; Sabatine MS
    Circulation; 2019 Apr; 139(17):2022-2031. PubMed ID: 30786725
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparing benefits from sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists in randomized clinical trials: a network meta-analysis.
    Sabouret P; Bocchino PP; Angelini F; D'Ascenzo F; Galati G; Fysekidis M; DE Ferrari GM; Fischman DL; Bhatt DL; Biondi-Zoccai G
    Minerva Cardiol Angiol; 2023 Apr; 71(2):199-207. PubMed ID: 35195376
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Randomized Evaluation of a Remote Management Program to Improve Guideline-Directed Medical Therapy: The DRIVE Trial.
    Blood AJ; Chang LS; Hassan S; Chasse J; Stern G; Gabovitch D; Zelle D; Colling C; Aronson SJ; Figueroa C; Collins E; Ruggiero R; Zacherle E; Noone J; Robar C; Plutzky J; Gaziano TA; Cannon CP; Wexler DJ; Scirica BM
    Circulation; 2024 Jun; 149(23):1802-1811. PubMed ID: 38583146
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association of Prescription Co-payment With Adherence to Glucagon-Like Peptide-1 Receptor Agonist and Sodium-Glucose Cotransporter-2 Inhibitor Therapies in Patients With Heart Failure and Diabetes.
    Essien UR; Singh B; Swabe G; Johnson AE; Eberly LA; Wadhera RK; Breathett K; Vaduganathan M; Magnani JW
    JAMA Netw Open; 2023 Jun; 6(6):e2316290. PubMed ID: 37261826
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of Sodium-Glucose Cotransporter-2 Inhibitor and Glucagon-Like Peptide-1 Receptor Agonist Prescribing in Patients With Diabetes Mellitus With and Without Cardiovascular Disease.
    Gay HC; Yu J; Persell SD; Linder JA; Srivastava A; Isakova T; Huffman MD; Khan SS; Mutharasan RK; Petito LC; Feinstein MJ; Shah SJ; Yancy CW; Kho AN; Ahmad FS
    Am J Cardiol; 2023 Feb; 189():121-130. PubMed ID: 36424193
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Risk of diabetic retinopathy and diabetic macular oedema with sodium-glucose cotransporter 2 inhibitors and glucagon-like peptide 1 receptor agonists in type 2 diabetes: a real-world data study from a global federated database.
    Eleftheriadou A; Riley D; Zhao SS; Austin P; Hernández G; Lip GYH; Jackson TL; Wilding JPH; Alam U
    Diabetologia; 2024 Jul; 67(7):1271-1282. PubMed ID: 38584180
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Network meta-analysis on the effects of finerenone versus SGLT2 inhibitors and GLP-1 receptor agonists on cardiovascular and renal outcomes in patients with type 2 diabetes mellitus and chronic kidney disease.
    Zhang Y; Jiang L; Wang J; Wang T; Chien C; Huang W; Fu X; Xiao Y; Fu Q; Wang S; Zhao J
    Cardiovasc Diabetol; 2022 Nov; 21(1):232. PubMed ID: 36335326
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prescribing in Type 2 Diabetes Patients With and Without Cardiovascular Disease History: A Descriptive Analysis in the UK CPRD.
    Farmer RE; Beard I; Raza SI; Gollop ND; Patel N; Tebboth A; McGovern AP; Kanumilli N; Ternouth A
    Clin Ther; 2021 Feb; 43(2):320-335. PubMed ID: 33581878
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative effectiveness of SGLT2i versus GLP1-RA on cardiovascular outcomes in routine clinical practice.
    Fu EL; Clase CM; Janse RJ; Lindholm B; Dekker FW; Jardine MJ; Carrero JJ
    Int J Cardiol; 2022 Apr; 352():172-179. PubMed ID: 35074492
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Underuse of cardiorenal protective agents in high-risk diabetes patients in primary care: a cross-sectional study.
    Hao R; Myroniuk T; McGuckin T; Manca D; Campbell-Scherer D; Lau D; Yeung RO
    BMC Prim Care; 2022 May; 23(1):124. PubMed ID: 35606699
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Deficits and Disparities in Early Uptake of Glucagon-Like Peptide 1 Receptor Agonists and SGLT2i Among Medicare-Insured Adults Following a New Diagnosis of Cardiovascular Disease or Heart Failure.
    Cromer SJ; Lauffenburger JC; Levin R; Patorno E
    Diabetes Care; 2023 Jan; 46(1):65-74. PubMed ID: 36383481
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The prescribing pattern of sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists in patient with type two diabetes mellitus: A two-center retrospective cross-sectional study.
    Korayem GB; Alshaya OA; Alghamdi AA; Alanazi SS; Almutib RT; Alsaileek M; Alrashidi A; Aldosari N; Bin Sheraim N; Al Yami MS; Almohammed OA
    Front Public Health; 2022; 10():1031306. PubMed ID: 36408008
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of GLP-1 receptor agonists on cardiovascular outcomes in patients with type 2 diabetes and chronic kidney disease: A systematic review and meta-analysis.
    Kelly M; Lewis J; Rao H; Carter J; Portillo I; Beuttler R
    Pharmacotherapy; 2022 Dec; 42(12):921-928. PubMed ID: 36271706
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Real-world characteristics, modern antidiabetic treatment patterns, and comorbidities of patients with type 2 diabetes in central and Eastern Europe: retrospective cross-sectional and longitudinal evaluations in the CORDIALLY
    Prázný M; Suplotova L; Gumprecht J; Kamenov Z; Fülöp T; Medvedchikov A; Rosenzweig D; Aleksandric M
    Cardiovasc Diabetol; 2022 Oct; 21(1):203. PubMed ID: 36209118
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Utilization Rates of SGLT2 Inhibitors and GLP-1 Receptor Agonists and Their Facility-Level Variation Among Patients With Atherosclerotic Cardiovascular Disease and Type 2 Diabetes: Insights From the Department of Veterans Affairs.
    Mahtta D; Ramsey DJ; Lee MT; Chen L; Al Rifai M; Akeroyd JM; Vaughan EM; Matheny ME; Santo KRDE; Navaneethan SD; Lavie CJ; Birnbaum Y; Ballantyne CM; Petersen LA; Virani SS
    Diabetes Care; 2022 Feb; 45(2):372-380. PubMed ID: 35015080
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel antidiabetic drugs in diabetic kidney disease accompanying type 2 diabetes - a minireview.
    Wieczorek-Surdacka E; Surdacki A; Świerszcz J; Chyrchel B
    Folia Med Cracov; 2020; 60(4):97-101. PubMed ID: 33821854
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Use of Sodium-Glucose Cotransporter 2 Inhibitors and Glucagonlike Peptide-1 Receptor Agonists in Patients With Diabetes and Cardiovascular Disease in Community Practice.
    Nanna MG; Kolkailah AA; Page C; Peterson ED; Navar AM
    JAMA Cardiol; 2023 Jan; 8(1):89-95. PubMed ID: 36322056
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combining glucagon-like peptide-1 receptor agonists (GLP-1RAs) and sodium-glucose cotransporter-2 inhibitors (SGLT2is) in patients with type 2 diabetes mellitus (T2DM).
    Gourdy P; Darmon P; Dievart F; Halimi JM; Guerci B
    Cardiovasc Diabetol; 2023 Apr; 22(1):79. PubMed ID: 37005640
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.